Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A single dose of DT120 — a pharmaceutical-grade LSD tablet — significantly slashed anxiety scores in a phase 3 trial, with benefits kicking in as early as day 2. The 214-patient Voyage trial showed a placebo-adjusted drop of 5.4 points on the HAM-A anxiety scale at 12 weeks, a result analysts flagged as a key benchmark for success. No new drug has been approved for GAD in nearly two decades.
A single dose of DT120 (lysergide) — a fast-dissolving, pharmaceutical-grade LSD tablet — delivered significant and sustained reductions in anxiety symptoms in adults with generalized anxiety disorder (GAD), according to positive topline results from the phase 3 Voyage trial. The randomized, double-blind, placebo-controlled study enrolled 214 adults with a baseline HAM-A score of 20 or higher, and the results were striking: patients on DT120 saw an 11.6-point drop in anxiety scores at week 12, compared to just 6.2 points for placebo — a statistically significant and clinically meaningful difference.
What makes the findings especially notable is the speed of onset. Clinical improvement was observed as early as day 2 post-dosing and held steady throughout the entire 12-week treatment period. The drug works by acting as a partial agonist at serotonin-2A receptors and is designed for infrequent, monitored dosing — a sharp contrast to the daily antidepressants and anti-anxiety medications currently used for GAD. No suicidality signal was observed.
By the Numbers:
Why it matters: GAD is one of the most common mental health conditions, yet treatment options have been stagnant for two decades. DT120's large effect size, rapid onset, and infrequent dosing model could represent a meaningful shift in psychiatric care — and it has already shown success in a separate late-stage depression trial.
